// App-Quantinova.ai

174 : Secukinumab demonstrates consistent safety over long-term exposure up to three years in patients with active ankylosing spondylitis: pooled analysis of three Phase III trials

Researchers

Presenter

  • Nick Barkham

Principal Investigators

  • Atul Deodhar

  • Xenofon Baraliakos

  • Helena Marzo-Ortega

  • Joachim Sieper

  • Mats Andersson

  • Brian Porter

  • Todd Fox

Medical Centers

  • Rheumatology, New Cross Hospital, Wolverhampton, UNITED KINGDOM

  • Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR

  • Rheumatology, Ruhr-University Bochum, Herne, GERMANY

  • NIHR Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UNITED KINGDOM

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

  • Rheumatology, Charite - Campus Benjamin Franklin, Berlin, Germany

  • Immunology & Dermatology Franchise, Novartis Pharma AG, Basel, SWITZERLAND

  • Immunology and Dermatology Franchise, Novartis Pharma AG, East Hanover, NJ

Locations

  • United Kingdom

  • United States

  • Germany

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01358175

  • NCT01649375

  • NCT02008916

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved